OncoC4, Inc.

United States · Pharmaceuticals

OncoC4, Inc. is a biotechnology company focused on developing innovative immunotherapies for hard-to-treat cancers and Alzheimer's disease. The company utilizes advanced scientific pathways involving immune checkpoints like CTLA-4, CD24, and Siglec to enhance the immune system's ability to identify and eliminate cancer cells. Their goal is to create safer and more effective therapies. The product pipeline includes a variety of therapeutic modalities such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR T-cell therapies. These treatments are designed to tackle the complexities of cancer and neurodegenerative diseases by targeting both innate and adaptive immune checkpoints. Founded by leading immunologists, OncoC4 is supported by a team with extensive experience in clinical development and business strategy. The company is headquartered in Rockville, Maryland, and is dedicated to advancing its clinical pipeline through research partnerships and investor collaborations.